Department of Psychiatry, Dokkyo Medical University, School of Medicine, Shimotsuga, Tochigi, Japan.
Address correspondence and reprint requests to Norio Yasui-Furukori, MD, PhD, Department of Psychiatry, Dokkoyo Medical University, School of Medicine, Mibu, Shimotsuga, Tochigi 321-0293, Japan; E-mail: [email protected]
Conflicts of Interest and Source of Funding: N.Y.-F. has been a speaker for Otsuka Pharmaceutical Co, Ltd; Mochida Pharmaceutical Co, Ltd; Dainippon-Sumitomo Pharmaceutical Co; and MSD Co. K.S. has received research support from Novartis Pharma K.K.; Dainippon Sumitomo Pharma Co; Astellas Pharma Inc; Meiji Seika Pharma Co, Ltd; Eisai Co, Ltd; Pfizer Inc; Otsuka Pharmaceutical Co, Ltd; Daiichi Sankyo Co; and Takeda Pharmaceutical Co, Ltd. K.S. has received honoraria from Eisai Co, Ltd; Mitsubishi Tanabe Pharma Corporation; Takeda Pharmaceutical Co, Ltd; Meiji Seika Pharma Co, Ltd; Janssen Pharmaceutical K.K.; Shionogi & Co, Ltd; Dainippon Sumitomo Pharma Co; Daiichi Sankyo Co; and Pfizer Inc. The funders did not have any role in data collection or in the study design and analysis, decision to publish, or preparation of the manuscript. The remaining authors declare that they have no competing interests to report.
Ethics Approval and Consent to Participate: The ethics committee of the School of Medicine at Dokkyo Medical University judged that there was no need to review this case.
Consent for Publication: Written informed consent was obtained from the patient for the publication of this case report.
Availability of Data and Materials: All data generated or analyzed during this study are included in this published article.
Author Contributions: Y.S., N.Y.-F, M.S. and H.O. were involved in the clinical investigations. N.Y.-F. wrote the manuscript. Y.S., N.Y.-F., and K.S. were involved in the literature review and revisions. All authors read and approved the final manuscript.
